Search Results

Your search for David M. O’Malley, MD, and Antonio Castaneda, MD matches 2 pages

Showing 1 - 2

By David M. O’Malley, MD, and Antonio Castaneda, MD / September 10, 2020 - Supplement: Gynecologic Cancers Almanac

Clinical Perspective on PAOLA-1: Maintenance Therapy for Advanced Ovarian Cancer

Based on multiple phase III prospective trials, there is evidence that both poly (ADP-ribose) polymerase (PARP) inhibitors and antiangiogenic therapies such as bevacizumab provide benefit when utilized in a maintenance strategy in the first-line treatment of advanced epithelial ovarian cancer (GOG...

gynecologic cancers

By David M. O’Malley, MD, and Antonio Castaneda, MD / May 10, 2020

PARP Inhibitors in Maintenance Treatment for Advanced Ovarian Cancer

Based on multiple phase III prospective trials, there is evidence that both PARP inhibitors and antiangiogenic therapies such as bevacizumab provide benefit when utilized in a maintenance strategy in the first-line treatment of advanced epithelial ovarian cancer (GOG 218, ICON7, SOLO-1, PRIMA,...

Apr

Today In Oncology

Search Results

Your search for David M. O’Malley, MD, and Antonio Castaneda, MD matches 2 pages

Clinical Perspective on PAOLA-1: Maintenance Therapy for Advanced Ovarian Cancer

PARP Inhibitors in Maintenance Treatment for Advanced Ovarian Cancer

Alectinib Approved as Adjuvant Treatment for ALK-Positive Non–Small Cell Lung Cancer

Professional Societies Introduce New Evidence-Based Guidelines on Testing Immunotherapy Biomarkers in NSCLC

Accelerated Aging May Be a Risk Factor for Early-Onset Cancers in Younger Generations

Novel MDM2 Inhibitor Shows Activity in Salivary Gland Cancers

Novel SPECT/CT Imaging Technique Under Study in Prostate Cancer